Stay updated on Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial

Sign up to get notified when there's something new on the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The study record was updated to add Janssen Scientific Affairs, LLC as a collaborator and remove the National Cancer Institute (NCI); recent timestamps indicate that the record has been refreshed.
    Difference
    0.3%
    Check dated 2026-05-01T09:10:45.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The page’s revision/version indicator was updated from v3.5.2 to v3.5.3.
    Difference
    0.1%
    Check dated 2026-04-24T06:44:18.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-17T02:58:06.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    Added 'Multiple myeloma' as a topic and included a new Resources link to Genetic and Rare Diseases Information Center.
    Difference
    0.2%
    Check dated 2026-04-02T16:16:53.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    Revision: v3.5.0 added; Revision: v3.4.3 removed.
    Difference
    0.1%
    Check dated 2026-03-19T08:58:58.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    Added Revision: v3.4.3; removed Revision: v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-12T04:58:39.000Z thumbnail image

Stay in the know with updates to Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page.